Sanofi, Formation Bio, and OpenAI Announce AI Collaboration

Paris, New York, and San Francisco, May 21, 2024. Sanofi, Formation Bio, and OpenAI are collaborating to develop AI software aimed at accelerating drug development. This initiative aims to bring new medicines to patients more efficiently by integrating data, software, and tuned models across the drug development lifecycle.

Sanofi will provide proprietary data to develop AI models, aspiring to be the first biopharma company powered by AI at scale. According to Sanofi CEO Paul Hudson, this collaboration is key to advancing their AI-powered drug development efforts.

OpenAI will offer its cutting-edge AI capabilities and expertise. Brad Lightcap, COO of OpenAI, emphasized the potential of AI to expedite drug development and bring new treatments to the market.

Formation Bio will contribute engineering resources and its tech-driven development platform. CEO Benjamine Liu believes this partnership can transform drug development productivity and pace.

This collaboration marks a significant step toward leveraging AI to improve drug development and bring new treatments to patients.